Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), is an unprecedented global health crisis. However, therapeutic options for …

Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …

Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have
raised concerns about resistance to neutralizing antibodies elicited by previous infection or …

The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in an unprecedented setback …

COVID-19 pandemic is caused by the novel coronavirus SARS-CoV-2. Angiotensin-
converting enzyme 2 (ACE2) is not only an enzyme but also a functional receptor on cell …

Antibodies elicited by infection accumulate somatic mutations in germinal centers that can
increase affinity for cognate antigens. We analyzed 6 independent groups of clonally related …

Abstract The coronavirus disease 2019 (COVID-19) pandemic presents an urgent health
crisis. Human neutralizing antibodies that target the host ACE2 receptor-binding domain …

Neutralizing antibodies (nAbs) elicited against the receptor binding site (RBS) of the spike
protein of wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are …

Background Progress in characterising the humoral immune response to Severe Acute
Respiratory Syndrome 2 (SARS-CoV-2) has been rapid but areas of uncertainty persist …